Business Context and Reporting Period
Company: Stevanato Group S.p.A.
Filing Type: Form 6-K (Interim Report)
Reporting Period: Three and nine months ended September 30, 2025
Business Overview: A global provider of drug containment, drug delivery, and diagnostic solutions. The Group operates two segments: Biopharmaceutical and Diagnostic Solutions (DCS, IVD, DDS) and Engineering (machinery and equipment). The company is currently expanding capacity in Fishers, Indiana (USA) and Latina (Italy) while optimizing its Engineering footprint.
Key Financial Metrics
| Metric (EUR million) | 3 Months Ended Sep 30, 2025 | 9 Months Ended Sep 30, 2025 |
|---|---|---|
| Revenue | 303.2 | 839.8 |
| Gross Profit | 88.5 | 237.0 |
| Gross Margin | 29.2% | 28.2% |
| Operating Profit | 52.7 | 128.7 |
| Operating Margin | 17.4% | 15.3% |
| Net Profit (Attributable to Parent) | 36.1 | 92.3 |
| Diluted EPS (EUR) | 0.13 | 0.34 |
| Operating Cash Flow | 47.2 | 192.0 |
| Capital Expenditures (CAPEX) | 54.9 | 193.7 |
| Cash and Cash Equivalents | 113.3 | 113.3 |
| Total Debt (Financial Liabilities) | 453.3 | 453.3 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 9.1% (Q3) and 8.6% (YTD) compared to the prior year periods. Growth was driven by the Biopharmaceutical and Diagnostic Solutions segment (+14.5% Q3, +11.7% YTD), specifically high-value solutions (+47.3% Q3, +28.5% YTD). The Engineering segment declined (-18.8% Q3, -8.8% YTD) due to lower revenue from glass converting and visual inspection lines.
- Profitability Expansion: Operating profit rose 28.5% (Q3) and 36.5% (YTD). Gross margin improved to 29.2% (Q3) and 28.2% (YTD) from 26.8% and 26.4% respectively, aided by a favorable product mix and recovery in vial demand.
- Segment Performance: The Biopharmaceutical segment operating margin improved to 22.1% (Q3) and 20.1% (YTD). Conversely, the Engineering segment reported a negative operating margin of -1.1% (Q3) and 1.2% (YTD) due to complex legacy projects and lower new order intake.
- Finance Costs: Net finance expenses increased significantly due to foreign exchange losses (USD depreciation against EUR) and higher interest expenses on new borrowings.
- Tax Rate: The effective tax rate decreased to 25.2% (YTD) from 27.4% (prior year) due to the "IRES premiale" tax benefit in Italy.
Guidance, Outlook, and Risks
- Capacity Expansion: The Group is ramping up new facilities in Fishers, Indiana, and Latina, Italy. Commercial production in Fishers began in Q3 2024, with line installations and validations expected to continue through 2026. Latina is preparing for ready-to-use cartridge production in 2026.
- China Strategy: The Group has postponed EZ-fill capacity expansion in China and entered a rent-to-buy agreement for its Zhangjiagang facility, planning to sell the asset to focus resources on US and Italian expansion.
- Engineering Optimization: A business optimization plan is underway for the Engineering segment to address execution challenges in Denmark, right-size operations, and harmonize processes. Financial performance remains below expectations due to project mix.
- Key Risks:
- Internal Controls: The Company disclosed that internal controls over financial reporting were not effective as of December 31, 2024, due to material weaknesses. Remediation is ongoing.
- Foreign Exchange: Significant exposure to USD, CNY, and MXN fluctuations. Recent USD depreciation negatively impacted reported results.
- Customer Destocking: Ongoing recovery from customer inventory destocking following the pandemic, though demand is gradually recovering.
- Geopolitical/Tariffs: Risks related to US-China trade relations and potential tariffs on products manufactured in various jurisdictions.
Investor Verification Checklist
- Remediation of Internal Controls: Verify the progress of the remediation plan for material weaknesses in internal controls over financial reporting.
- Engineering Segment Turnaround: Monitor the Engineering segment's ability to return to profitable growth as the optimization plan executes and legacy projects conclude.
- High-Value Mix Sustainability: Assess the sustainability of the revenue mix shift toward high-value solutions (syringes, EZ-fill) and its impact on long-term margins.
- FX Sensitivity: Evaluate the impact of continued USD/EUR volatility on future earnings, given the significant US revenue exposure.
- Capital Allocation: Review the execution of the ~EUR 105 million in committed CAPEX orders and the timeline for ROI on the Fishers and Latina expansions.